<DOC>
	<DOCNO>NCT02241044</DOCNO>
	<brief_summary>Background : A second endoscopic method add injection therapy recommend high-risk bleeding peptic ulcer . Many endoscopic device prove useful hemostatic instrument , whereas hemostatic efficacy argon plasma coagulation ( APC ) widely investigate . Aim : This study design know whether additional APC treatment could influence hemostatic efficacy endoscopic injection therapy treat high-risk bleeding ulcer . Methods : From October 2010 January 2012 , eligible patient high-risk bleed ulcer admit hospital . They prospectively randomly underwent either APC therapy plus distilled water injection distil water injection alone . Pantoprazole infusion conduct fasting period endoscopy orally 8 week encourage ulcer healing . Episodes rebleeding retreat endoscopic combination therapy . Patients benefit retreatment underwent emergency surgery transarterial embolization ( TAE ) .</brief_summary>
	<brief_title>Argon Plasma Coagulation Bleeding Peptic Ulcers</brief_title>
	<detailed_description>Patients method Study cohort Patients acute upper gastrointestinal bleeding ( AUGIB ) admit Kaohsiung Veterans General Hospital January 2011 January 2012 screen . Inclusion criterion ( ) 20 year age ( ii ) patient high-risk peptic ulcer bleeding . Acute hemorrhage upper gastrointestine define classical presentation hematemesis , coffee-ground emesis , and/or melena . High-risk bleeding ulcer define participant stigmata bleed visible vessel ( eg , spurt , ooze ) , non-bleeding visible vessel ( NBVV ) adherent clot.4 A NBVV endoscopy define raise red , red-blue pale hemispheric vessel protrude ulcer bed , without active bleeding . An adherent clot define overlie blood clot resistant vigorous irrigation . Exclusion criterion follow : ( ) presence another possible bleeding site ( eg , gastroesophageal varix , gastric cancer , reflux esophagitis ) ; ( ii ) coexistence actively severe ill disease ( eg , septic shock , stroke , myocardial infarction , surgical abdomen ) ; ( iii ) treatment anticoagulant ( eg , warfarin ) ; ( iv ) pregnancy ; ( v ) presence operate stomach ; ( vi ) refusal participate study . In current study , baseline characteristic study group collect first 24 hour admission . Some definition event express herein : smoking define inhalation smoke burn tobacco daily recent 3 month ; habitual consumption alcohol define participant imbibe alcohol twice per week recent 3 month ; shock consider systolic blood pressure le 90 mm Hg diastolic le 60 mmHg , heart rate 100 beat per minute ; comorbid diseases include unresolved malignancy , diabetes mellitus , liver cirrhosis , uremia , congestive heart failure , chronic pulmonary obstructive disease pneumonia ; coagulopathy define prothrombin time &gt; 14 second and/or activate partial thromboplastin time &gt; 45 second . Randomization In prospective , parallel-group , randomize control trial , eligible patient randomize two group use opaque-sealed envelope number accord table random number fist therapeutic endoscopy ( index endoscopy ) : Combined group Injection group . Informed consent obtain enrolled participant . Combined group patient receive APC therapy follow distilled water injection index endoscopy . Injection group patient underwent distilled water alone index endoscopy . Thereafter treatment group treat intravenous pantoprazole ( Pantoloc i.v. , Nycomed GmbH , Singen , Germany ) 40 mg every 12 hour first 3 day , follow oral pantoprazole ( Pantoloc , Takeda GmbH , Oranienburg , Germany ) 40 mg daily end 56-day study period . Primary end point rebleeding . Secondary end point include initial hemostasis , need surgery , transfusion requirement , period hospitalization , severe adverse event ( stricture , obstruction perforation ) death 30 day postrandomization .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Peptic Ulcer Hemorrhage</mesh_term>
	<criteria>( ) 20 year age ( ii ) patient highrisk peptic ulcer bleeding . ( ) presence another possible bleeding site ( eg , gastroesophageal varix , gastric cancer , reflux esophagitis ) ; ( ii ) coexistence actively severe ill disease ( eg , septic shock , stroke , myocardial infarction , surgical abdomen ) ; ( iii ) treatment anticoagulant ( eg , warfarin ) ; ( iv ) pregnancy ; ( v ) presence operate stomach ; ( vi ) refusal participate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>argon plasma coagulation , bleed peptic ulcer</keyword>
</DOC>